Home›Trial›NCT05599191
NCT05599191Phase 3ACTIVE NOT RECRUITING

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions
CoughRefractory Chronic Cough
Interventions / Drugs
BLU-5937Placebo
View on ClinicalTrials.gov ↗
Sponsor
BLU
BELLUS Health
Chronic Cough
C60/100
Study Details
Enrollment825 participants
Primary Completion—
Lead SponsorBellus Health Inc. - a GSK company
Data Retrieved2026-04-11 04:07:59.947174+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 825 participants
Sponsor Catalyst Profile

BELLUS Health (BLU) is the sponsoring company for this trial. BiotechSign currently grades this company C (60/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BLU Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.